Logo

BGM

BGM Group Ltd.

BGM

BGM Group Ltd. • NASDAQ
$7.70 ▼ -2.16% (-0.17)
Market Cap $1.54 B
52w High $17.17
52w Low $7.00
Dividend Yield 0%
P/E -26.55
Volume 3.29K
Outstanding Shares 200.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2024 $12.563M $2.093M $328.78K 2.617% $0.045 $-679.088K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $18.141M ▼ $53.004M ▲ $8.91M ▲ $42.744M ▼
Q2-2024 $25.355M ▲ $49.852M ▼ $4.931M ▼ $43.432M ▲
Q4-2023 $22.419M ▲ $51.258M ▼ $6.907M ▼ $42.792M ▼
Q2-2023 $8.88M ▼ $64.234M ▼ $9.498M ▼ $52.846M ▼
Q4-2022 $14.319M $64.527M $9.563M $53.052M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow

Five-Year Company Overview

Income Statement

Income Statement BGM’s income statement is very small in scale and sits close to break‑even. Revenue over the past few years has been low and slightly declining, with only a thin layer of gross profit. Operating profit and EBITDA hover around zero, which means the core business is not yet clearly profitable. Net results swing between tiny profits and small losses, so reported earnings per share can look very volatile even when the underlying change is modest. Overall, the income statement shows a company in transition, without yet having a strong or stable profit engine from either the legacy pharmaceutical side or the new AI activities.

Balance Sheet

Balance Sheet The balance sheet is light and simple. Total assets are modest and have edged down from earlier years, pointing to a relatively small operational footprint. Cash levels are low but steady, and the company carries little to no financial debt, so leverage risk is limited for now. Equity makes up most of the capital structure, which suggests the business has been funded more by shareholders than by borrowing. The small size of the balance sheet means both flexibility and vulnerability: there is not much debt pressure, but also not a large cushion if integration costs or investments run higher than expected.

Cash Flow

Cash Flow Cash flow is essentially flat, reflecting a business that has not yet turned its operations into reliable cash generation. Operating cash flow has hovered around break‑even, with only a brief period of clearly positive cash. Free cash flow mirrors this pattern, since capital spending is very low and does not materially change the picture. This indicates BGM is not currently burning large amounts of cash, but also not generating the kind of surplus needed to comfortably fund aggressive expansion on its own. Future integration of acquisitions and scaling of AI platforms will likely be key to whether cash flows move decisively into positive territory or not.

Competitive Edge

Competitive Edge Competitively, BGM is trying to reinvent itself from a small pharmaceutical and chemical producer into a technology‑driven player at the intersection of healthcare, insurance, and AI. This is an ambitious move into markets that are large but also crowded with well‑funded technology and insurance firms. BGM’s differentiation comes from its attempt to link pharmaceutical know‑how, health products, and AI‑enabled insurance services into one ecosystem. However, its moat is still emerging rather than established. The strategy relies heavily on acquisitions and rapid expansion, which could create a unique platform if well integrated, but also exposes the company to execution risk and strong competitive pushback from incumbents.

Innovation and R&D

Innovation and R&D Innovation is the clearest strength of BGM’s current story. Management is leaning hard into AI, big data, and intelligent systems, especially through platforms aimed at automating and improving insurance processes. The company is also exploring a mix of biotech and consumer health, including premium dark tea and potential medicinal products, and branching into areas like intelligent robots and cloud‑based services. Much of this innovation is being acquired rather than built slowly in‑house, which can speed up capabilities but also complicates culture, technology integration, and focus. The pipeline of ideas and technologies is broad; the main uncertainty is whether BGM can prioritize effectively and turn this innovative portfolio into scalable, profitable offerings.

Summary

BGM is a very small, fast‑changing company shifting away from a traditional pharmaceutical base toward an AI‑centric model serving insurance and healthcare. Financially, it operates close to break‑even with thin margins, a light balance sheet, and cash flows that neither strongly burn nor strongly generate cash. Strategically, it is pursuing a bold, acquisition‑driven plan to build an ecosystem that blends AI insurance platforms, health products, and intelligent services. This creates meaningful upside potential but also considerable execution and integration risk, especially given the company’s limited financial scale. Key things to watch include how well acquisitions are integrated, whether AI platforms gain real commercial traction, how quickly the new businesses can become meaningfully profitable, and whether the company can maintain financial flexibility while it pursues this high‑speed transformation.